このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Erasca 将来の成長

Future 基準チェック /06

Erascaの収益は年間8.7%で減少すると予測されていますが、年間収益は年間76.4%で増加すると予測されています。EPS は年間増加すると予測されています。自己資本利益率は 3 年後に-50% 4.3%なると予測されています。

主要情報

-8.7%

収益成長率

4.3%

EPS成長率

Biotechs 収益成長	24.7%
収益成長率	76.4%
将来の株主資本利益率	-50.0%
アナリストカバレッジ	Good
最終更新日	20 May 2024

今後の成長に関する最新情報

Recent updates

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Sep 23

Erasca adds 10% ahead of R&D Day

Sep 07

Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers

Jul 18

We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Apr 12

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Dec 28

業績と収益の成長予測

NasdaqGS:ERAS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-194	-191	N/A	4
12/31/2025	N/A	-168	-168	-162	5
12/31/2024	N/A	-150	-84	-33	5
3/31/2024	N/A	-127	-109	-108	N/A
12/31/2023	N/A	-125	-123	-101	N/A
9/30/2023	N/A	-231	-125	-103	N/A
6/30/2023	N/A	-236	-127	-103	N/A
3/31/2023	N/A	-240	-132	-104	N/A
12/31/2022	N/A	-243	-120	-103	N/A
9/30/2022	N/A	-138	-121	-99	N/A
6/30/2022	N/A	-149	-125	-99	N/A
3/31/2022	N/A	-141	-112	-90	N/A
12/31/2021	N/A	-123	-98	-80	N/A
9/30/2021	N/A	-154	-103	-70	N/A
6/30/2021	N/A	-119	-81	-54	N/A
3/31/2021	N/A	-96	-81	-43	N/A
12/31/2020	N/A	-102	-71	-33	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ERAS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ERAS今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ERAS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ERAS来年は収益がないと予測されています。

高い収益成長: ERAS来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ERAS 3 年以内に赤字になると予測されています。

Erasca 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 11% to US$6.25

Price target decreased by 7.4% to US$9.00

Price target decreased by 19% to US$11.50

Price target decreased by 9.3% to US$15.57

Price target decreased to US$18.60

Recent updates

Erasca, Inc. Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma

Independent Director recently bought US$182k worth of stock

Price target decreased by 11% to US$6.25

New major risk - Shareholder dilution

Erasca, Inc. has completed a Follow-on Equity Offering in the amount of $159.999999 million.

New minor risk - Shareholder dilution

Erasca, Inc., Annual General Meeting, Jun 20, 2024

Insufficient new directors

New major risk - Revenue and earnings growth

Erasca, Inc. announced that it expects to receive $45 million in funding

Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?

Erasca, Inc. Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

Erasca, Inc. Receives FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Co-Founder recently bought US$1.7m worth of stock

Price target decreased by 7.4% to US$9.00

Erasca, Inc. Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Co-Founder recently bought US$2.0m worth of stock

New minor risk - Share price stability

Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth

Co-Founder recently bought US$275k worth of stock

New minor risk - Share price stability

Price target decreased by 19% to US$11.50

Erasca, Inc. Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

Erasca, Inc. Announces Promising Preliminary Data for ERAS-007 Combinations in Patients with Gastrointestinal Malignancies as Part of Two Poster Presentations That Will Be Presented At the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois

Erasca, Inc. Further Strengthens Business Leadership with Two Key Promotions

Independent Director recently bought US$55k worth of stock

Price target decreased by 9.3% to US$15.57

Co-Founder recently bought US$284k worth of stock

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Co-Founder recently bought US$231k worth of stock

Co-Founder recently bought US$200k worth of stock

Price target decreased to US$18.60

Erasca, Inc. Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors

Erasca forms clinical trial partnership with Pfizer for cancer therapy

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Erasca, Inc. Announces Preliminary Data for Eras-007 and Eras-601 in Braf-Driven and Ras/Mapk-Altered Solid Tumors

Erasca adds 10% ahead of R&D Day

Erasca, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination

Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers

Erasca, Inc.(NasdaqGS:ERAS) dropped from Russell 2000 Growth Index

Erasca, Inc. Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven Cancers

Erasca, Inc. Announces Key Appointments

Erasca Appoints Jean Liu to its Board of Directors

We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Erasca, Inc. Announces FDA Clearance of IND Application for Eras-801 in Glioblastoma Multiforme

Erasca, Inc. Announces First Patient Dosed in HERKULES-3, A Phase 1B/2 Gastrointestinal Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

Erasca, Inc. has completed an IPO in the amount of $300 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘